Organon & Co (OGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Organon & Co (OGN) has a cash flow conversion efficiency ratio of 0.106x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($107.00 Million) by net assets ($1.01 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Organon & Co market cap and net worth for the company's overall valuation and market capitalisation.
Organon & Co - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Organon & Co's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Organon & Co Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Organon & Co ranked by their cash flow conversion efficiency. Explore Organon & Co earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dolby Laboratories
NYSE:DLB
|
0.134x |
|
Amneal Pharmaceuticals, Inc. Class A Common Stock
NYSE:AMRX
|
0.144x |
|
QL Resources Bhd
KLSE:7084
|
0.012x |
|
Amylyx Pharmaceuticals Inc
NASDAQ:AMLX
|
-0.131x |
|
Ottobock SE & Co. KGaA
XETRA:OBCK
|
0.133x |
|
Axcelis Technologies Inc
NASDAQ:ACLS
|
0.017x |
|
RUBIS
F:BYN
|
N/A |
|
Krones AG
XETRA:KRN
|
0.010x |
Annual Cash Flow Conversion Efficiency for Organon & Co (2018–2025)
The table below shows the annual cash flow conversion efficiency of Organon & Co from 2018 to 2025. View OGN share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $752.00 Million | $700.00 Million | 0.931x | -53.21% |
| 2024-12-31 | $472.00 Million | $939.00 Million | 1.989x | +117.43% |
| 2023-12-31 | $-70.00 Million | $799.00 Million | -11.414x | -1086.66% |
| 2022-12-31 | $-892.00 Million | $858.00 Million | -0.962x | +40.99% |
| 2021-12-31 | $-1.51 Billion | $2.46 Billion | -1.630x | -508.87% |
| 2020-12-31 | $5.49 Billion | $2.19 Billion | 0.399x | +1.36% |
| 2019-12-31 | $7.04 Billion | $2.77 Billion | 0.393x | -32.28% |
| 2018-12-31 | $6.35 Billion | $3.69 Billion | 0.581x | -- |
About Organon & Co
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive… Read more